YUCAIPA, Calif., Sept. 8, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company received an aggregate valuation of as much as $28M from the FINRA licensed Investment Banking firm Pacific Pearl Group.
On September 1, 2009, David Yang, Senior Vice President of the Pasadena, California-based investment banking group, Pacific Pearl Group, provided the company with the valuation documents indicating that their aggregate valuation performed on Ingen was $17M-$28M. "Extensive research involved examining the competitive landscape. The search of comparables involved extensive discussions on 'comparables', as IGNT is very different from the majority of medical device companies focused on the respiratory market; the value of the company is not reflected in LTM sales," stated David Yang, Senior Vice President of Pacific Pearl Group.
The Pacific Pearl Group is also assessing potential strategic acquirers both domestically and internationally. There are several interested companies that are private based corporations with annual earnings ranging from $40M-$60M that have an interest and are in discussions with the Pacific Pearl Group. The Pacific Pearl Group will determine the financial and strategic fit for these companies.
"The Pacific Pearl Group plays a very important part of any future acquisition of Ingen Technologies. The new Oxyview Nasal Cannula has provided an increasing revenue base and has positioned Ingen within the respiratory industry and has attracted various acquirers," stated Scott Sand, CEO and Chairman of the Board of Ingen Technologies.
http://www.pacpearl.com/index.html
About Ingen Technologies/Oxyview:
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.